Purpose-The aims of this study were to determine prevalence of and factors associated with any human papillomavirus (HPV) and vaccine-type HPV among young men after vaccine introduction, stratified by vaccination status.
Introduction
Human papillomavirus (HPV) infects nearly 14 million people each year in the United States; almost half of infections occur in [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] year olds.(1) Infection may cause anogenital warts, anogenital cancers such as cervical cancer, and oropharyngeal cancers. The Centers for Disease Control and Prevention estimates that approximately 30,700 new cancers each year are attributable to HPV, including 11,600 cancers in men. (2) Male HPV vaccination is effective, and could greatly decrease the burden of anogenital warts and cancers caused by HPV in men as well as decrease the disease burden in young women through herd immunity. (3, 4) In 2011, the Advisory Committee on Immunization Practices (ACIP) recommended routine vaccination of young men 11-21 years old and vaccination of young men 22-26 years old at high risk for HPV.(3) However, HPV vaccine coverage in young men is low. In 2015, only 49.8% of [13] [14] [15] [16] [17] year old men in the U.S. had received at least one dose of the vaccine and 28.1% had completed the series. (5) Previous studies have demonstrated that the prevalence of any HPV among men ranges widely (1.3% to 72.9%) but is typically greater than 20%. (6) Surveillance studies have demonstrated a decrease in HPV in women and adult men after vaccine introduction. (7, 8) However, there are limited data available regarding the prevalence of HPV in adolescent men after vaccine introduction. Most studies have been conducted in adult men (i.e. men at least 18 years of age) or in young men who have sex with men (MSM).(9, 10) Furthermore, there are limited data regarding which factors are associated with HPV infection, and previous studies were conducted primarily in adults. These have demonstrated that factors associated with HPV infection include lifetime and recent number of sexual partners, (9) (10) (11) (12) (13) (14) (15) lack of circumcision, (11) (12) (13) (14) inconsistent condom use, (12, 13, (15) (16) (17) smoking, (12, 15) and younger age. (11) Finally, little is known about concordance between anogenital sites in young men. (18) Information regarding the epidemiology and risk factors for HPV infection in adolescent and young adult men after vaccine licensing is essential for policy decisions, public health messaging, and prevention efforts. For example, HPV epidemiology is likely to change after HPV vaccine introduction, and current data regarding HPV prevalence in vaccinated and unvaccinated young men are important for guiding policies regarding immunization, decisions about vaccine financing, and the design of public health messages for clinicians and parents. In addition, risk factors for HPV may differ after vaccine introduction because vaccinated and unvaccinated men may differ in terms of demographic characteristics, behaviors, or other factors that are associated with their risk for HPV. Information about changing risk factors is important for public health messaging and designing interventions to prevent HPV post-vaccination. Therefore, the aims of this study were to: (1) determine the prevalence of anogenital HPV, and concordance between genital sites, in a diverse sample of [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] year old sexually active adolescent and young adult men and (2) determine factors associated with a) any anogenital HPV (≥ 1 type) among all young men, and b) vaccine-type HPV among all, vaccinated, and unvaccinated young men. We hypothesized that prevalence of HPV would be high in this study sample, that having received at least one HPV vaccine dose would be associated with lower prevalence of vaccine-type HPV, and that factors associated with vaccine-type HPV would differ among vaccinated and unvaccinated men.
Methods
Young men 13-26 years old (N=400) were recruited between 2013 and 2015 from a hospital-based teen health center (THC) and a health department sexually transmitted disease (STD) clinic in Cincinnati, Ohio, U.S. Both sites serve a racially diverse, urban, and predominantly low income population. Men who had sexual contact (genital-oral or genitalgenital with male or female partners) were eligible to participate. All vaccinated men had received the 4-valent vaccine. Men were recruited using a sequential sampling strategy (all eligible men were invited to participate): 91% of those approached agreed to participate. The study was approved by the Institutional Review Boards of the hospital and the health department, and written informed consent was obtained from participants. Participants completed a survey instrument in English or Spanish assessing sociodemographic characteristics, HPV and HPV vaccine knowledge, vaccination history, substance use history, and sexual behaviors. The survey was developed and validated in similar populations: details are described in previous manuscripts. (19) (20) (21) Three separate genital swabs (penile, including coronal sulcus, glans penis, and shaft of the penis, as well as scrotal) and one perianal/anal swab were collected from each male participant for HPV DNA testing using previously-described procedures.(22) Swabs were pre-moistened with sterile saline, placed immediately into tubes containing 1 mL of Digene Specimen Transport Medium (STM, Qiagen, Germantown, MD), and stored at −80°C. The three penile/scrotal samples were combined to produce one genital DNA extract per participant, and the perianal/anal sample was analyzed separately. This method has been shown to optimize HPV detection among men and to result in reproducible detection of genital HPV in men, while achieving cost savings. (22, 23) Samples were analyzed for HPV genotypes using the Roche Linear Array Assay, a polymerase chain reaction amplification technique that uses an L1 consensus primer system and reverse-line blot detection strip to identify 36 different HPV genotypes (Roche Molecular Systems, Alameda, CA).(24) The Roche Linear Array tests for 37 high-risk and low-risk genotypes (6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 73, 81, 82, 83, 84 , IS39, and CP6108): IS39 has been reclassified as a subtype of HPV82, so the test detects 36 distinct genotypes. The HPV test results from genital (penile and scrotal) and perianal/anal sites were analyzed separately for descriptive analyses, but were combined for univariable and multivariable analyses due to insufficient power to analyze type-specific HPV prevalence by site in the multivariable analyses.
The primary outcome variables for this study were any HPV (≥ 1 type) and 4-valent vaccinetype HPV (HPV6, 11, 16, and/or 18) . Independent variables included vaccination status, number of vaccine doses, demographic factors (age, race, ethnicity, insurance status, type of insurance), recruitment site (THC vs. STD clinic), sexual behaviors (lifetime number of female and male partners; recent number of female and male partners; recent number of new female and male partners; age of first sexual intercourse with male and female partners; recent condom use with men and women; condom use at last sexual intercourse; recent history of giving or receiving oral sex), sexual orientation, substance use (recent and lifetime cigarette smoking, recent and lifetime marijuana smoking), and history of other sexually transmitted infections. These independent variables were chosen based on biological plausibility and/or because they have been associated with HPV and other STIs in previous studies. (10, 11, 13-17, 25, 26) Any HPV, type-specific HPV (types included in the 4-valent and 9-valent vaccines, nonvaccine-type, high-risk, HPV16/18, and HPV6, 11, 16 and 18), and vaccination rates were determined using descriptive statistics. HPV results were then stratified by site (penile/ scrotal vs. perianal/anal), age (13-21 vs. 22-26 years), and vaccination status. We also examined the association between number of vaccine doses and vaccine-type HPV using logistic regression.
Associations between independent and outcome variables were determined using chi-square, Fisher's exact and Wilcoxon rank-sum tests. Independent variables associated at p<0.10 with outcome variables in univariable analyses were checked for multicollinearity and eliminated from multivariable analysis when appropriate. Variables associated with four outcomes (≥ 1 HPV type among all participants, and vaccine-type HPV among all, vaccinated, and unvaccinated participants) at p<0.10 in univariable analysis were included in four multivariable logistic regression models. Stepwise variable selection was used and variables associated with the outcomes at p<0.05 were retained in the final models.
HPV vaccine doses. Data addressing the first aim of the study are shown in Table 1 . Among all participants, 59.4% were positive for ≥ 1 HPV type, 26% for ≥ 1 4-valent vaccine type, 18.9% for HPV16, and 4.5% for HPV18 (Table 1) . HPV prevalence in vaccinated vs. unvaccinated young men was: any HPV (50.5% vs. 62.6%, p=.03), 4-valent vaccine-type HPV (20.4% vs. 27.9%, p=.13), 9- . Among participants positive for anogenital HPV, results were generally discordant when stratified by site (penile/scrotal vs. perianal/anal). For example, among the 75 men positive for HPV16, 39 (52%) were positive at the genital site only, 27 (36%) at the anal site only, and 9 (12%) at both sites. (Table 1 ). There were no statistically significant differences in HPV by age.
Factors associated with ≥ 1 HPV type among all young men
In univariable analyses the following factors were significantly associated with positivity for ≥ 1 HPV type ( Table 2) : vaccination status, recruitment from STD clinic vs. THC, higher lifetime number of female partners, higher number of new male partners in the past 3 months, inconsistent condom use, higher frequency of oral sex in the past 3 months, history of STI, lifetime smoking, recent smoking, and recent marijuana use. In multivariable logistic regression the variables independently associated with HPV positivity were higher frequency of oral sex in the past 3 months, recent smoking, and history of STI (Table 3) .
Factors associated with vaccine-type HPV among all, vaccinated, and unvaccinated young men
In univariable analysis, the factors significantly associated with vaccine-type HPV among all young men included: ever had sexual intercourse with a male partner, homosexual or bisexual preference, higher number of male partners (any and new) in the past 3 or 12 months, and history of gonorrhea (Table 4 ). Although unvaccinated men were more likely than vaccinated men to be positive for vaccine type HPV, the difference was not statistically significant. In multivariable logistic regression, factors independently associated with vaccine-type HPV among all participants were White vs. Black race and a history of gonorrhea (Table 5 ). In univariable analyses, factors significantly associated with vaccinetype HPV among vaccinated young men included: private (vs. Medicaid or no) insurance, having had sexual intercourse with a male partner, higher number of male partners in the past 12 months, having a male main sexual partner, and identification as bisexual or homosexual vs. heterosexual (Table 4 ). In multivariable logistic regression, factors independently associated with vaccine-type HPV among vaccinated young men were private vs. Medicaid insurance and private vs. no insurance ( Table 5 ). In univariable analyses, factors significantly associated with vaccine-type HPV in unvaccinated young men included: history of gonorrhea, history of herpes, and higher number of new male partners in the past 3 months (Table 4 ). In multivariable logistic regression analyses one factor was independently associated with vaccine-type HPV among unvaccinated participants: history of gonorrhea (Table 5 ).
Discussion
In this study, we examined the prevalence of and factors associated with any HPV infection and vaccine-type HPV infection, as well as HPV type concordance between anogenital sites, in a diverse sample of adolescent and young adult men. The study provides novel data about HPV epidemiology in young men, two to four years after HPV vaccination was recommended for young men in the U.S.
As hypothesized, the prevalence of HPV was high in this study sample: 59% were positive for at least one HPV type, 26% for at least one 4-valent vaccine-type HPV, 23 (28) The prevalence of any HPV in our study was similar to what was reported in these studies, and the prevalence of HPV16 and/or HPV18 was even higher, despite the fact that a small proportion of the men in our study were MSM and they were recruited after vaccine introduction.
Although limited data have been published regarding HPV prevalence among men younger than 18 years, two studies have examined HPV incidence in this age group. In a study of [16] [17] [18] [19] [20] year-old men who have sex with men, the incidence rate for any anal HPV infection was 57 and for vaccine-type anal HPV was 33 cases per 100 person-years, and in an study of [16] [17] [18] [19] [20] [21] [22] [23] [24] year-old men, the incidence rate of vaccine-type HPV was 9 cases per 100 person-years. (29, 30) Together with our findings of high HPV prevalence in young men, these data suggest that higher vaccination rates are needed to achieve the benefits of vaccination.
We recruited a sample of young women during the same time period, with similar demographic characteristics and from comparable clinical sites. In young women, the prevalence of ≥ 1 HPV type was higher (67.4%), but the prevalence of 4-valent vaccine-type HPV much lower (8.7%) as was the prevalence of HPV 16/18 (7.3%). (7) The higher vaccine-type HPV prevalence in young men vs. women is likely due to the five-year lag between vaccine recommendations in women and men, and the resulting higher rates of vaccination in women (71.3% in women vs. 26% in men). ) The relatively high discordance found in our study could be due to sexual behaviors: most study participants practiced only vaginal sex with women, and had never had anal sex with a women or man. Other factors that may influence concordance rates include HPV sampling and detection methods and study population characteristics.
Recent studies have demonstrated that introduction of HPV vaccines greatly decreases HPV prevalence. (34) Young men participating in this study who were vaccinated, compared to those who were unvaccinated, had a significantly lower prevalence of any HPV infection (50.5% vs. 62.6%). Although those who were vaccinated compared to those who were unvaccinated also had a lower prevalence of vaccine-type HPV, the differences were not statistically significant. This finding may be explained by the fact that many of these young men had not been fully vaccinated and may have acquired vaccine-type HPV prior to vaccination: prophylactic HPV vaccines are most effective if given prior to sexual initiation. It is also possible that we had insufficient power to detect differences in vaccine-type HPV by vaccination status due to the relatively small number of vaccinated men who were infected with vaccine-type HPV (N=21). We are conducting surveillance studies in this population, and expect that we will observe a protective effect in young men with a larger number of participants and when vaccination rates are higher. Vaccination rates in this sample were described in more detail in a previous publication, (35) Factors associated with HPV infection in these young men included higher frequency of recent oral sexual encounters, recent smoking, and history of an STI. The association between oral sex and anogenital HPV may be due to direct oral-genital transmission or be a marker of higher exposure to sexual behaviors that would put young men at risk for HPV transmission. In a recent systematic review and meta-analysis of oral HPV infection in men who have sex with men, the authors found that while a proportion of men were concordant for oral and anogenital HPV, type-specific concordance between oral and anogenital sites was rare. (37) Given that HPV-associated oropharyngeal cancer incidence rates are rising, especially in men, a better understanding of oral-genital transmission patterns in young men, the natural history of oral HPV in men, and the pathogenesis of HPV-associated oropharyngeal cancer will be important to design interventions that will reverse this trend. (38) Several recent studies have confirmed an association between smoking and HPV infection in men. (12, 15) Furthermore, Schabath et al demonstrated that current smoking was associated with higher incidence of genital HPV infection. (39) In MSM, smoking is associated with a higher viral load of high-risk HPV types, abnormal anal cytology, and an increased risk for anal cancer. (40) Given the strong association between number of sexual partners and HPV infection, (11) (12) (13) (14) (15) it is not surprising that history of an STI is associated with HPV infection.
Finally, we identified factors associated with prevalent vaccine-type HPV by vaccination status, and as hypothesized, factors differed among vaccinated and unvaccinated men. Moreira et al. examined risk factors for incident vaccine-type HPV among heterosexual adolescent and young adult men, and found that that higher number of sexual partners, less frequent condom use, and living in Africa were associated with incident HPV. (30) In our study, sexual behaviors (including male sexual partners and number of male partners) were associated with prevalent vaccine-type HPV in univariable, but not multivariable analyses. Among all participants, White race and history of gonorrhea were associated with vaccinetype HPV; among vaccinated participants, private insurance was associated with vaccinetype HPV; and among unvaccinated participants, history of gonorrhea was associated with vaccine-type HPV. Those participants recruited from the STD clinic, compared to those recruited from the THC, were older, more likely to be White, more likely to have private insurance, and less likely to have been vaccinated. They were also more likely to be positive for HPV. These factors may explain why White race and private insurance were associated with HPV infection. A history of gonorrhea may be a marker for riskier sexual behaviors that could increase HPV acquisition. The fact that we could not identify a set of modifiable risk factors for HPV or vaccine-type HPV suggests that it is challenging to determine who is at risk for HPV, underscoring the importance of primary prevention through vaccination and counseling about limiting sexual partners and consistent condom use.
There are several limitations to this study. The design is cross-sectional; therefore, we cannot draw conclusions from the results about causality. Behaviors were self-reported which may limit validity. Participants were recruited from clinical sites, which diminishes the generalizability of the findings; it is possible that HPV prevalence is higher in those not accessing clinical care. The sample size was relatively small, limiting our ability to detect significant associations between independent variables and HPV infection. Although we used established methods for anogenital sampling and reliable HPV DNA testing methods, as noted in the Methods section, there are limitations to all HPV testing methods and it is possible that there were false positives or false negatives. Furthermore, we only tested HPV at one point in time. Finally, we tested a limited number of HPV DNA genotypes, so it should be noted that throughout the manuscript when we refer to "any HPV," this actually signifies any HPV among the types detected by the Roche Linear Array test.
Conclusion
Any and vaccine-type HPV prevalence were high and vaccination coverage was low among young men in this study sample, two to four years after the vaccine was introduced. Furthermore, our analyses did not identify a set of risk factors associated with vaccine-type HPV that could be targeted in interventions. Our findings emphasize the importance of primary prevention of HPV through increasing vaccination rates in young men and vaccinating before sexual initiation. The findings also suggest that interventions to promote STI prevention such as limiting sexual partners and using condoms consistently will be important, though challenging.
Implications and Contributions
Few studies have examined the prevalence and risk factors for HPV and concordance between genital sites in adolescent males after vaccine introduction. This study demonstrates that HPV prevalence was high and vaccination rates low among young men 2-4 years after vaccine introduction, underscoring the importance of vaccination according to national guidelines. Table 1 Type-specific HPV prevalence by anatomical site Ever had sex with a male partner 0.01
